All In Biotech

Drug Trial Radar · NCT05199129

Clinical Efficacy and Safety Evaluation of HCP1904-3 in Essential Hypertension Patients

A Multi-center, Randomized, Double-blinded, Active-Controlled, Parallel, Phase III Study to Evaluate the Efficacy and Safety of HCP1904-3 in Essential Hypertension Patients

Last checked: Nov 19, 2026Latest source record: Sep 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 166 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

166

Actual

Start

Nov 17, 2021

Primary completion

Sep 14, 2022

Study completion Sep 14, 2022

Sponsor

Sponsor type
Industry
First posted
Jan 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate of efficacy and safety of HCP1904-3 and RLD2001-1 alone in patients with essential hypertension inadequately controlled on RLD2001-1 monotherapy.

Conditions

  • Hypertension

Interventions

  • HCP1904-3Drug

    Take once daily for 8 weeks orally

  • RLD2001-1Drug

    Take once daily for 8 weeks orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in mean sitting systolic blood pressure(mmHg)Time frame: Week 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Severance Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.